Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
BETHLEHEM, Pa., May 10, 2017 -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference.
“Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.”
Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier.
Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings.
“Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1
Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
1 Data on file
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]
